* Veracyte Inc VCYT.OQ VCYT.O is expected to show a rise
in
quarterly revenue when it reports results on May 4.
* The South San Francisco California-based company is
expected to
report a 11.8% increase in revenue to $75.808 million from
$67.78 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Veracyte Inc is for
a
loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 6.1%
in the last three months.
* Wall Street's median 12-month price target for Veracyte
Inc is
$34, above its last closing price of $20.96.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.15 -0.15 -0.05 Beat 67
Sep. 30 2022 -0.24 -0.25 -0.12 Beat 51.7
Jun. 30 2022 -0.22 -0.22 -0.13 Beat 40.5
Mar. 31 2022 -0.24 -0.24 -0.20 Beat 15.9
Dec. -0.18 -0.16 -0.15 Beat 6.9
31 2021
Sep. 30 2021 -0.17 -0.16 -0.20 Missed -21.2
Jun. 30 2021 -0.25 -0.25 -0.13 Beat 48.4
Mar. 31 2021 -0.12 -0.12 -0.11 Beat 8.3
This summary was machine generated May 3 at 02:04 GMT. All
figures in US dollars unless otherwise stated